The PEPPER trial, in contrast, applies a personalized adjuvant immunoglobulin therapy (IgGAM) in postoperative peritonitis patients, stratifying treatment response according to biomarker-defined inflammation and immune status, including IL-6, HLA-DR, immunoglobulin levels, NF-κB1, and others [107]. This evidence concerns the gene NFKB1 and peritonitis.